Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 5/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22362132 | 0.88 | KMT2A (0.59) | LTA4HCYSLTR2CYSLTR1BRD4PDK2 | |
| SCHEMBL5847214 | 0.86 | KMT2A (0.58) | FFAR1LTA4HCYSLTR2CYSLTR1BRD4 | |
| SCHEMBL20211766 | 0.84 | CYSLTR2 (0.55) | FFAR1LTA4HCYSLTR2CYSLTR1BRD4 | |
| SCHEMBL20211781 | 0.84 | CYSLTR2 (0.55) | FFAR1LTA4HCYSLTR2CYSLTR1BRD4 | |
| SCHEMBL766897 | 0.83 | MAPT (0.58) | LTA4HCYSLTR2CYSLTR1BRD4KMT2A | |
| SCHEMBL1250165 | 0.82 | ALB (0.63) | FFAR1CYSLTR2CYSLTR1PDE3BPDE3A | |
| SCHEMBL8630858 | 0.82 | ALDH1A1 (0.51) | — | |
| SCHEMBL7273053 | 0.81 | ALDH1A1 (0.54) | — | |
| SCHEMBL4253341 | 0.81 | CYSLTR2 (0.60) | LTA4HCYSLTR2CYSLTR1BRD4PDE3B | |
| SCHEMBL7632059 | 0.81 | CYSLTR2 (0.64) | FFAR1LTA4HCYSLTR2CYSLTR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1768694-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2007-04-04 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| WO-2006082245-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| WO-2006005683-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | FFAR1 3423/4885LTA4H 4310/4885CYSLTR2 4380/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | FFAR1 591/4885LTA4H 2565/4885CYSLTR2 4071/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | FFAR1 991/4885LTA4H 3403/4885CYSLTR2 4182/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | FFAR1 814/4885LTA4H 2787/4885CYSLTR2 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.